Novartis AG (NVS)

Novartis said on Wednesday it intends to build a radioligand therapy manufacturing site in Texas, expanding its U.S. footprint with what will be its first such facility in the state and fifth nationwide.

Fox Run Management L.L.C. purchased a new position in Novartis AG (NYSE: NVS) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 12,349 shares of the company's stock, valued at approximately $1,584,000. Other hedge funds and other institutional investors have also recently

Novartis' business is resilient, as evidenced by its ability to grow sales despite a major patent cliff. The Swiss healthcare giant's income program is another great attraction for long-term investors.

Basel, February 23, 2026 – Novartis will present data from five key abstracts evaluating the highly selective oral Bruton's tyrosine kinase inhibitor (BTKi) Rhapsido® (remibrutinib) in chronic spontaneous urticaria (CSU) and as an investigational therapy for peanut allergy at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA, from February 27 to March 2, 2026. These presentations provide more evidence on the use of Rhapsido in CSU, as well as its potential in other indications and highlight Novartis commitment to addressing unmet needs in patients with immune-mediated diseases. New analyses on the impact of Rhapsido on disease control and early symptom relief from the Phase III REMIX-1 and REMIX-2 trials in CSU will be presented. Additionally, the first presentation of Phase II FA data for remibrutinib, focusing on IgE‑mediated peanut allergy, will be featured in an oral session. Plans are in progress to begin the Phase III program in FA in 2026. “These food allergy (FA) data further strengthen the evidence supporting remibrutinib as a novel, well-tolerated, oral option for patients with allergic and immune-mediated diseases, complementing the recent FDA approval in chronic spontaneous urticaria (CSU) and underscoring its broader therapeutic potential,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. "Our priority is advancing therapies for patients who have few alternatives and expanding the reach of innovative medicines to transform care across multiple, high-need disease areas."  Regulatory reviews for remibrutinib for the treatment of CSU are underway in several regions, including the European Union and Japan. In addition to FA, remibrutinib is in clinical development for chronic inducible urticaria (CIndU) and hidradenitis suppurativa (HS). FDA submission for remibrutinib in symptomatic dermographism, the most prevalent type of CIndU, was completed in Q4 2025. Additionally, positive topline results were announced for the remaining two arms of the CIndU Phase III RemIND trial. In the coming months, the full data set will be submitted to health authorities globally, and the RemIND trial findings will be presented at upcoming medical congresses. Abstracts accepted by AAAAI include:

Novartis is a large drugmaker with a wide-ranging portfolio. Like all drugmakers, it faces the challenge of patent expirations.

Novartis (NVS) is once again intersecting with US trade policy after President Donald Trump said his tariff strategy may have influenced the Swiss drugmaker's d

Novartis (NVS) has agreed to divest its 70.68% stake in Novartis India Ltd. to a consortium of WaveRise Investments, ChrysCapital Fund X and Two Infinity Partne

Novartis (NVS) is taking another step in its ongoing reshuffle, agreeing to sell its entire 70.68% stake in Novartis India for roughly $159 million to a private

China Universal Asset Management Co. Ltd. increased its position in Novartis AG (NYSE: NVS) by 33.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 20,000 shares of the company's stock after acquiring an additional 5,000 shares during the period.

U.S. President Donald Trump said he met Vas Narasimhan, the chief executive officer of Swiss drugmaker Novartis , at the White House on Wednesday.

Swiss pharmaceutical firm Novartis said on Friday that it would sell its entire 70.68% stake in its listed Indian unit to a consortium of WaveRise Investments, ChrysCapital and Two Infinity Partners.

HighTower Advisors LLC increased its stake in shares of Novartis AG (NYSE: NVS) by 4.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 253,203 shares of the company's stock after purchasing an additional 10,543 shares during the

Unnatural Products said on Wednesday it has signed a licensing agreement with Novartis to develop macrocyclic peptide-based therapies for a cardiovascular program.

SANTA CRUZ, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced a research collaboration and licensing agreement with Novartis on an undisclosed program.

Basel, February 18, 2026 – Novartis today announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU)1. The primary endpoint was met for the three most prevalent types of CIndU: symptomatic dermographism, cold urticaria and cholinergic urticaria, achieving significantly higher complete response rates versus placebo at Week 121. These data represent an important advance in the treatment of CIndU, demonstrating the potential of remibrutinib to be the first targeted therapy for CIndU and address a major unmet need.

Ameritas Advisory Services LLC cut its stake in Novartis AG (NYSE: NVS) by 61.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,271 shares of the company's stock after selling 5,134 shares during the quarter. Ameritas Advisory Services LLC's holdings